Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Citalopram and Reboxetine on Urethral and Anal Closure
NCT04097288Phase 1Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Sep 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of citalopram in fecal incontinence (FI) (3 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoints: Difference in average Urethral Opening Pressure (UOP) during relaxation and Difference in average Anal Opening Pressure (AOP) during relaxation. Started Sep 2019; status: completed.
02
Drugs
citalopram
03
Conditions
fecal incontinence (FI)
Beyond the preview
Go deeper on NCT04097288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097288.